Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: seminole who wrote (1093)	8/17/1998 10:31:00 AM
From: David Cathcart	Read Replies (1) \| Respond to of 1826

For those who do not follow the MOGN thread on Yahoo, the NCI has now listed two of their MGI 114 trials on their web-site. Here is the site for the NCI sponsored phase II trial for MGI 114 in advanced renal cell carcinoma: cancernet.nci.nih.gov Here is the site covering the NCI sponsored phase I trial for pediatric patients with recurrent or refractory solid tumors: cancernet.nci.nih.gov More NCI sponsored trials are due to begin soon. MGI Pharma has not made an announcement regarding the beginning of the NCI sponsored trials. This could mean that they are still only enrolling patients in the subject trials and that actual dosing has not begun yet. Or, MGI Pharma is simply choosing to be low key about the event. Whatever the case, it is good to see that the NCI is beginning to foot much of the bill to see if tiny MGI Pharma has a big cancer drug on its hands. David

To: seminole who wrote (1093)	8/18/1998 6:15:00 PM
From: David Cathcart	Read Replies (1) \| Respond to of 1826

Richard, I just had a conversation with Lori Weiman. A few interesting comments: * Both phase I trials for MGI 114 are still ongoing. While they have realized the MTD of MGI 114, and thus they have begun phase II, several patients are still being treated in phase I so they cannot conclude a trial while the patients are still in the program. One patient with pancreatic cancer is in his fourth month of treatment. Other patients, one with head & neck, have shown signs of efficacy. She said the fact that the phase I trials are still ongoing is bitter-sweet. It is good that some patients are apparently benefiting from the drug and thus remain in the trial. The fact that the patients remain though prevents MGI from concluding the trial and compiling and publishing the results. As a PR person, she wants that information to distribute. * The NCI just posted their MGI 114 trials on their web-site last Friday. The NCI does not advise MGI Pharma of when they are going to post the trials and begin enrolling patients in a given trial. Additional trails will be posted in the near future, but the best way to find out about them is to continue to check the NCI web-site. * Very positive negotiations are in progress for the Euro deal. Lori was very careful in what she said but the optimism was evident. * They have been working on a web-site for sometime. One issue holding it up is that they are working out details with the FDA about exactly what can be said about certain drugs (i.e. Salagen for Sjogren's). At this point you can only see the cover page: mgipharma.com Volume has slowed to a crawl with MOGN, but I'm not worried. Good things are in store. Let's shrink some tumors!!! David